Nitrosourea efficacy in high-grade glioma: A survival gain analysis summarizing 504 cohorts with 24193 patients

Journal of Neuro-Oncology

Volumn 88, Issue 1, 2008, Pages 57-63

  Wolff, Johannes E A ^a   Berrak, Su ^b   Koontz Webb, Susannah E ^a   Zhang, Ming ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MARMARA UNIVERSITY   (Turkey)

Author keywords

1 (2 Chloroethyl) 3 (2,6 dioxo 3 piperidyl); Carmustine; Glioblastoma multiforme; Lomustine; Nimustine; Ranimustine; Survival gain

Indexed keywords

1 (2 CHLOROETHYL) 3 (2,6 DIOXO 3 PIPERIDYL) 1 NITROSOUREA; ANTINEOPLASTIC AGENT; CARMUSTINE; CHLOROETHYLNITROSOUREA; FOTEMUSTINE; LOMUSTINE; NIMUSTINE; NITROSOUREA DERIVATIVE; RANIMUSTINE; TEMOZOLOMIDE;

AGE; ARTICLE; BRAIN RADIATION; BRAIN SURGERY; CANCER GRADING; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG RESPONSE; GENDER; GLIOBLASTOMA; GLIOMA; HUMAN; MONOTHERAPY; OLIGODENDROGLIOMA; PROGNOSIS; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; BRAIN NEOPLASMS; CARMUSTINE; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; DATABASES, FACTUAL; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; LOMUSTINE; MALE; NIMUSTINE; NITROSOUREA COMPOUNDS; REPRODUCIBILITY OF RESULTS; SELECTION BIAS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 42349089115     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9533-5     Document Type: Article

References (19)

1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996
2. Hauch H, Sajedi M, Wolff JE (2005) Treatment arms summarizing analysis of 220 high-grade glioma studies. Anticancer Res 25:3585-3590
3. Thompson SG, Higgins JP (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21:1559-1573
4. van der Heijden GJ, Donders AR, Stijnen T, Moons KG (2006) Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: A clinical example. J Clin Epidemiol 59:1102-1109
5. Pope WB, Sayre J, Perlina A et al (2005) MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 26:2466-2474
6. Korshunov A, Sycheva R, Golanov A (2005) The prognostic relevance of molecular alterations in glioblastomas for patients age <50 years. Cancer 104:825-832
7. Stark AM, Nabavi A, Mehdorn HM et al. (2005) Glioblastoma multiforme-report of 267 cases treated at a single institution. Surg Neurol 63:162-169; discussion 169
8. Wagner S, Warmuth-Metz M, Emser A et al. (2006) Treatment options in childhood pontine gliomas. J Neurooncol 79:281-287
9. Wrensch M, Rice T, Miike R et al (2006) Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area. Neuro-oncol 8:12-26
10. Rubin DB (2004) Multiple imputation for nonresponse in surveys, Wiley-Interscience, June
11. Grossman SA, O'Neill A, Grunnet M et al (2003) Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 21:1485-1491
12. Westphal M, Ram Z, Riddle V et al (2006) Gliadel wafer in initial surgery for malignant glioma: Long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 148:269-275; discussion 275
13. Levin VA, Silver P, Hannigan J et al (1990) Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18:321-324
14. Sweetman S (2006) The complete drug reference. Greenwood Village, Thomson Micromedex
15. Wakabayashi T, Kajita Y, Mizuno M et al (2001) Efficacy of adjuvant therapy with procarbazine, MCNU, and vincristine for oligodendroglial tumors. Neurol Med Chir (Tokyo) 41:115-119; discussion 119-120
16. Preuss I, Thust R, Kaina B (1996) Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs. Int J Cancer 65:506-512
17. Laquerriere A, Raguenez-Viotte G, Paraire M et al (1991) Nitrosoureas lomustine, carmustine and fotemustine induced hepatotoxic perturbations in rats: Biochemical, morphological and flow cytometry studies. Eur J Cancer 27:630-638
18. De Vita VTCP, Owens AH Jr, Gold GL, Krant MJ, Edmonson J (1965) Clinical trials with 1,3-Bis(2-chloroethyl)-1-nitrosourea, NSC-409962. Cancer Res 25:1876-1881
19. Wolff JE, Trilling T, Molenkamp G et al (1999) Chemosensitivity of glioma cells in vitro: A meta analysis. J Cancer Res Clin Oncol 125:481-486